Properties of Styrene–Maleic Anhydride Copolymer Compatibilized Polyamide 66/Poly (Phenylene Ether) Blends : Effect of Maleic Anhydride Concentration and Copolymer Content

Polyamide 66 (PA66)/poly (2,6-dimethyl-1,4-phenylene ether) (PPE) blends with a ratio of 50/50 (w/w) were produced by a twin-screw compounder. The immiscible blends were compatibilized using two different styrene–maleic anhydride copolymers (SMA) with a low (SMAlow) and a high (SMAhigh) maleic anhydride (MA) concentration of 8 and 25 wt%, respectively. Furthermore, the SMA content was varied from 0 to 10 wt%. The influence of MA concentration and SMA content on the morphological and thermomechanical properties of PA66/PPE blends was investigated. Herein, we established correlations between the interfacial activity of the SMA with blend morphology and corresponding tensile properties. A droplet-sea to co-continuous morphology transition was shown by scanning electron microscopy to occur between 1.25 and 5 wt% in the case of SMAhigh. For SMAlow, the transition started from 7.5 wt% and was still ongoing at 10 wt%. It was found that SMAlow with 10 wt% content enhanced the tensile strength (10%) and elongation at break (70%) of PA66/PPE blends. This improvement can be explained by the strong interfacial interaction of SMAlow within the blend system, which features the formation of nanoemulsion morphology, as shown by transmission electron microscopy. Very small interdomain distances hinder matrix deformations, which forces debonding and cohesive failure of the PPE phase as a “weaker” main deformation mechanism. Due to a lack of interfacial activity, the mechanical properties of the blends with SMAhigh were not improved

Low-Density Polybutylene Terephthalate Foams with Enhanced Compressive Strength via a Reactive-Extrusion Process

Due to their appealing properties such as high-temperature dimensional stability, chemical resistance, compressive strength and recyclability, new-generation foams based on engineering thermoplastics such as polyethylene terephthalate (PET) and polybutylene terephthalate (PBT) have been gaining significant attention. Achieving low-density foams without sacrificing the mechanical properties is of vital importance for applications in the field of transportation and construction, where sufficient compressive strength is desired. In contrast to numerous research studies on PET foams, only a limited number of studies on PBT foams and in particular, on extruded PBT foams are known. Here we present a novel route to extruded PBT foams with densities as low as 80 kg/m3 and simultaneously with improved compressive properties manufactured by a tandem reactive-extrusion process. Improved rheological properties and therefore process stability were achieved using two selected 1,3,5-benzene-trisamides (BTA1 and BTA2), which are able to form supramolecular nanofibers in the PBT melt upon cooling. With only 0.08 wt % of BTA1 and 0.02 wt % of BTA2 the normalized compressive strength was increased by 28% and 15%, respectively. This improvement is assigned to the intrinsic reinforcing effect of BTA fibers in the cell walls and struts

Extruded Polystyrene Foams with Enhanced Insulation and Mechanical Properties by a Benzene-Trisamide-Based Additive

Low thermal conductivity and adequate mechanical strength are desired for extruded polystyrene foams when they are applied as insulation materials. In this study, we improved the thermal insulation behavior and mechanical properties of extruded polystyrene foams through morphology control with the foam nucleating agent 1,3,5-benzene-trisamide. Furthermore, the structure⁻property relationships of extruded polystyrene foams were established. Extruded polystyrene foams with selected concentrations of benzene-trisamide were used to evaluate the influence of cell size and foam density on the thermal conductivity. It was shown that the addition of benzene-trisamide reduces the thermal conductivity by up to 17%. An increase in foam density led to a higher compression modulus of the foams. With 0.2 wt % benzene-trisamide, the compression modulus increased by a factor of 4 from 11.7 ± 2.7 MPa for the neat polystyrene (PS) to 46.3 ± 4.3 MPa with 0.2 wt % benzene-trisamide. The increase in modulus was found to follow a power law relationship with respect to the foam density. Furthermore, the compression moduli were normalized by the foam density in order to evaluate the effect of benzene-trisamide alone. A 0.2 wt % benzene-trisamide increased the normalized compression modulus by about 23%, which could be attributed to the additional stress contribution of nanofibers, and might also retard the face stretching and edge bending of the foams

The local clinical validation of a new lithium heparin tube with a barrier: BD Vacutainer® Barricor LH Plasma tube

Introduction: Although serum-providing blood tubes with a barrier are still widely used due to their significant advantages, the use of blood tubes with a barrier to provide plasma is becoming widespread. We compared 22 analytes in a BD Vacutainer® Barricor LH Plasma tube for local clinical validation of this new lithium heparin tube with a barrier. Materials and methods: Samples from 44 volunteers were collected in different tubes (Becton Dickinson and Company): Z tube without additive (reference), clot-activator tube with gel (SST), lithium heparin tube without gel (LiH), and lithium heparin tube with barrier (Barricor). Analyte concentrations in different tubes were compared with the reference tube. All tubes were also evaluated according to additional testing (different centrifugation durations, blood-sampling techniques and individual differences). Results: Aspartate aminotransferase (AST), glucose (Glc), potassium (K), lactate dehydrogenase (LD), sodium (Na), and total protein (TP) had a significant bias in Barricor (9.19%, - 3.24%, - 4.88%, 21.60%, - 0.40%, 5.03%, respectively) relative to the reference tube. There was no statistical difference between different centrifugation durations and individual differences for AST, K and LD in LiH and/or Barricor (P > 0.05). There was a significant bias for LD between LiH and Barricor in terms of blood-sampling techniques (21.2% and 12.4%, respectively). Conclusions: Recently, the use of plasma has become prominent due to some of its advantages. In this study, plasma AST, K, LD, Glc and TP levels in Barricor were clinically different in comparison to serum. The results of additional tests showed that higher levels of LD in Barricor did not result from haemolysis, and they might be related to other factors including number of platelets, cellular fragility, or functional environment

Production and Molecular Characterization of Plasmodium falciparum Recombinant Circumsporozoite Protein with 37 NANP and 4 NVDP Epitopes

Malaria is caused by the protozoan parasite Plasmodium, the leading cause of death amongst the parasitic diseases. The disease is transmitted to human by the bites of female Anopheles mosquitoes. According to the World Health Organization (WHO) data, there were an estimated 214 million malaria cases and estimated 438.000 deaths occurred worldwide, in 2015. It is observed that 90% of all the deaths due to malaria occur in Africa. 78% of these cases were children who are under five years old. Intensive malaria interventions helped to reduce malaria incidence by 37% between 2000 and 2015. Malaria is a curable disease if diagnosed and treated promptly and correctly. Drug resistance has developed against almost all anti-malarial drugs and an effective vaccine against malaria has not been developed yet. Vaccine studies initiated 40 years ago by sterile immunity against falciparum malaria through immunization by exposure to 1000 irradiated mosquitoes. Complex structures, complicated life cycles and various antigenic structures of Plasmodium species make vaccination studies difficult. Circumsporozoite protein (CSP), the most extensively studied protein is also present in the content of the vaccine candidate RTS,S which is currently closest to get license. CSP was the first described Plasmodium antigen because of its important role during initiation of the parasitic infection. CSP is the major surface coat protein of Plasmodium parasite. CSP is a soluble protein and recombinant form of the CSP can be produced in Escherichia coli. NANP repeat region is a target site for host antibodies. Recently many DNA, RNA and protein vaccine candidates are being developed against malaria. According to WHO, in the next 20 years period, malaria vaccine can be developed. In this study we aimed to produce recombinant CSP (rCSP). Initially, P.falciparum CSP gene was amplified by PCR. CSP gene was cloned in to the pJET cloning vector. The gene subcloned to the pET100 protein expression vector. E.coli cells were used for protein expression. After this process, purification and endotoxin removal protocols were performed. As a result, 1182 bp CSP gene was obtained from P.falciparum genomic DNA. Accuracy of cloning and DNA sequence of the CSP gene was determined with DNA sequence analysis. The gene sequence was recorded to the GenBank with a registration no KT315396. rCSP was expressed in E.coli cells. The existence of rCSP was verified with Western Blot method and was purified and removed from endotoxins. rCSP aminoacid sequence and 3D shape was obtained. We believe that the production of recombinant CSP will enable us to contribute to the further malaria vaccine studies in our laboratory and country